Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis

INTRODUCTION: Ixekizumab, a humanized interleukin-17A antibody, has shown efficacy in ankylosing spondylitis (AS), with a greater proportion of ixekizumab-treated patients achieving an ASAS40 (Assessment of Spondyloarthritis International Society 40) endpoint compared to placebo. An ASAS40 response...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip, Walsh, Jessica A., Baraliakos, Xenofon, Inman, Robert, de Vlam, Kurt, Wei, James Cheng-Chung, Hunter, Theresa, Gallo, Gaia, Sandoval, David, Zhao, Fangyi, Dong, Yan, Bolce, Rebecca, Marzo-Ortega, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702662/
https://www.ncbi.nlm.nih.gov/pubmed/31254223
http://dx.doi.org/10.1007/s40744-019-0165-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702662/
https://www.ncbi.nlm.nih.gov/pubmed/31254223
http://dx.doi.org/10.1007/s40744-019-0165-3

Ejemplares similares